Aggrenox Oral Capsule, Extended Release 25-200Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Aggrenox: Oral capsule, extended release (25-200mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_2393.JPG
Aggrenox 25mg-200mg ER Cap
Boehringer Ingelheim Pharmaceuticals Inc
Pill Identification: LOGO 01A 

What is this Medicine?

ASPIRIN; DIPYRIDAMOLE (AS pir in; dye peer ID a mole) is used to decrease the risk of stroke in patients who have had a stroke or transient ischemic attack. A transient ischemic attack is also known as a TIA or mini-stroke.

CVS Pharmacy Patient Statistics for Aggrenox: Oral capsule, extended release(25-200mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Aggrenox 25mg-200mg Extended-Release Capsule

NDC: 005970001
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Transient Ischemic Attack (TIA), Ischemic Stroke, Stroke Prophylaxis

Storage Information
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Aggrenox 25mg-200mg Extended-Release Capsule
Drug Image file DrugItem_2393.JPG
Boehringer Ingelheim Pharmaceuticals Inc
Pill Identification: LOGO 01A 
Shape: capsule
Color: red,yellow

Reported Side Effects for Aggrenox 25mg-200mg Extended-Release Capsule

Deafness Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Lightheadedness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Breathing Difficulties Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Yellow Skin Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Increased Blood Sugar Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Blood In The Urine Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Hole In Intestines Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Kidney Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Stomach Ulcer Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Paresthesias Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Coughing Up Blood Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Bruise Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Fever Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Coma Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Gallstones Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low Blood Pressure Incidence:
<1.0%*
Severity: MODERATE
Onset: RAPID
Ringing In Ears Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Distressed Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Fluid In Lungs Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Itching Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Bleeding In The Brain Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
Bruises Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Drowsiness Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Fainting Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Hemorrhoids Incidence:
1.0%*
Severity: MODERATE
Onset: DELAYED
Confusion Incidence:
1.0%*
Severity: MODERATE
Onset: EARLY
Anemia Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Loss Of Memory Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Melena Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Feeling Sick Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Heart Failure Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Nose Bleed Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Bleeding Incidence:
3.0%*
Severity: MODERATE
Onset: EARLY
Intestinal Bleeding Incidence:
4.1%*
Severity: SEVERE
Onset: DELAYED
Back Pain Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
8.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
16.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
18.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
18.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
39.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Aggrenox 25mg-200mg Extended-Release Capsule

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Alcohol and Aggrenox 25mg-200mg Extended-Release Capsule(Aspirin)
Alcohol and Salicylates(Aspirin)
Side effects from this drug may get worse if you drink alcohol-containing drinks. If you have persistent stomach upset, vomit blood or what looks like coffee grounds, or have black, tarry stools, contact your health care provider immediately. Avoid alcohol containing drinks while taking aspirin. Alcohol intake should be limited even with short term use of aspirin or related pain relievers.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Aggrenox

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.